Denosumab Granted European Approval for Myeloma
Based on data from the Phase 3 482 trial, denosumab (Xgeva) has been approved for an expanded indication by the European Commission for the prevention of skeletal-related events in adult patients with multiple myeloma, according to Amgen, the developer of the RANK ligand inhibitor.
Read full article (External website)
Leave a Reply
Want to join the discussion?Feel free to contribute!